stockrow
Friday 6 November 2026
Export BBIO’s income statement to Excel — free account
BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
74.05
0.22
−0.30%
Follow BBIO
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
13.64 | 20.45 | 24.94 | 29.18 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(292.03) | (205.09) | (73.32) | (259.66) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
14.06 | 22.15 | 26.65 | 31.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(36.03) | (36.36) | (34.81) | (35.70) | |
EV/FCF |
(35.14) | (35.58) | (34.07) | (34.94) | |
Quick Ratio |
1.96 | 1.09 | 1.40 | 2.52 | |
Current Ratio |
2.09 | 1.23 | 1.52 | 2.77 | |
Net Debt/EBITDA |
(45.13) | (11.60) | (9.58) | (9.26) | |
Debt/Assets |
89.23% | 158.35% | 140.49% | 197.91% | |
Debt/Equity |
(1.17) | (0.77) | (0.85) | (0.89) | |
Asset Turnover |
0.60 | 0.62 | 0.51 | 0.54 | |
Operating CF/Net income |
0.53 | 0.47 | 1.20 | 0.29 | |
Capex/Depreciation |
(0.10) | (0.15) | (0.02) | (0.01) | |
Interest Coverage |
(0.21) | (1.96) | (2.01) | (2.77) | |
Research and Development Expense of Revenue |
40.63% | 61.33% | 65.10% | 75.51% | |
Selling, General and Administrative Expense of Revenue |
56.87% | 76.44% | 84.26% | 102.53% | |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.02 | 0.03 | |
Share Based Compensation of Revenue |
11.29% | 18.09% | 17.09% | 22.47% | |
Graham Net Nets |
(0.14) | (0.18) | (0.17) | (0.15) | |
Graham Number |
30.09 | 32.06 | 31.30 | 30.36 | |
Earnings Yield |
(4.62%) | (4.79%) | (5.04%) | (4.94%) | |
Free Cash Flow Yield |
(2.93%) | (3.04%) | (3.14%) | (3.11%) | |
Revenue per Share |
1.80 | 1.24 | 1.00 | 0.81 | |
Operating CF per Share |
(0.23) | (0.36) | (1.01) | (0.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.23) | (0.37) | (1.01) | (0.29) | |
Cash per Share |
7.85 | 3.68 | 4.83 | 3.07 | |
Shareholders Equity per Share |
(8.43) | (12.79) | (11.64) | (10.84) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(8.43) | (12.79) | (11.64) | (10.84) | |
Free Cash Flow |
(44.46) | (71.54) | (197.35) | (56.45) | |
Working Capital |
1,067.37 | 202.49 | 424.93 | 509.78 | |
Capital Expenditures |
(0.29) | (0.44) | (0.07) | (0.03) | |
Net Current Asset Value |
(1,769.32) | (2,629.04) | (2,397.60) | (2,214.29) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
245.80 | 165.68 | 160.25 | 72.08 | |
Average Payables |
53.48 | 26.67 | 28.29 | 22.92 | |
Average Inventory |
42.12 | 35.56 | 18.47 | — | |
Average Assets |
1,580.02 | 1,148.74 | 1,126.31 | 927.68 | |
Average Common Equity |
(2,258.69) | (2,141.42) | (1,953.18) | (1,766.88) |
Columns are period end dates · fundamentals updated 5 Nov 2026